Login to Your Account



Morphosys Signs $818M Celgene Deal for MOR202

By Cormac Sheridan
Staff Writer

Wednesday, July 3, 2013
Shares in Morphosys AG surged by more than 17 percent during trading last week on news of a deal with Celgene Corp. for its anti-CD38 multiple myeloma antibody MOR202, worth an immediate €127 million (US$165.5 million) and which could be worth up to €628 million in total.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription